Skip to main
HYPR

Hyperfine (HYPR) Stock Forecast & Price Target

Hyperfine (HYPR) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Hyperfine is a strong buy for investors as the company has proven sales and revenue, with continued growth expected through advancements in technology. The Swoop System, approved for use in various clinical settings, has shown significant positive results in reducing MRI turnaround time and is expected to reach breakeven in a short timeline. However, risks such as competition and regulatory approvals should be considered by potential investors.

Bears say

Hyperfine is an innovative medical device company with potential to revolutionize patient care through its portable, affordable, and clinically relevant AI-powered MRI technology. However, there are some fundamental factors that could negatively impact its operations, including regulatory risks, slow adoption of its Swoop system, and lumpiness in quarterly performance due to a relatively small and developing install base. Additionally, Hyperfine will need to effectively execute and ramp up revenue to reach its projected growth, which may be challenging given the longer sales cycle for hospitals and the competitive landscape in the medical device industry.

Hyperfine (HYPR) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hyperfine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hyperfine (HYPR) Forecast

Analysts have given Hyperfine (HYPR) a Buy based on their latest research and market trends.

According to 4 analysts, Hyperfine (HYPR) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.74, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.74, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hyperfine (HYPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.